medigraphic.com
ISSN 2992-779X (Electronic)
ISSN 2007-6452 (Print)

2018, Number 3

<< Back

Investigación en Discapacidad 2018; 7 (3)

The role of the immune system in the development of sepsis after burns

Cortés H, Muñoz B

Language: English
References: 50
Page: 110-116
PDF size: 686.90 Kb.


ABSTRACT

Burns are a destructive form of trauma that remain a major cause of morbidity and mortali-ty worldwide; despite the improvements in medical care, burns often leave lifelong physi-cal and emotional sequelae. Likewise, infectious complications, including sepsis and septic shock are common in patients with moderate to severe burn injuries. In this regard, sepsis is a life-threatening disturbance produced by a dysregulated reaction to infections, which can cause serious complications and lead to death. Therefore, the study of patho-physiological mechanisms related to development of sepsis is pivotal. In this article, we perform a comprehensive description of immune processes associated with burn injury, particularly the mechanisms involved in the development of sepsis after burns. In addition, we provide relevant information about immune mediators potentially useful as biomarkers of sepsis


REFERENCES

  1. Peck MD. Epidemiology of burns throughout the world. Part I: Distribution and risk factors. Burns 2011; 37:1087–1100.

  2. Mock C, Peck M, Krug E, Haberal M. Con-fronting the global burden of burns: A WHO plan and a challenge. Burns 2009; 35:615–617.

  3. Dissanaike S, Rahimi M. Epidemiology of burn injuries: Highlighting cultural and socio-demographic aspects. International Review of Psychiatry 2009; 21:505–511.

  4. Evers LH, Bhavsar D, Mailänder P. The biol-ogy of burn injury. Experimental Dermatolo-gy 2010; 19:777–783.

  5. Keck M, Herndon DH, Kamolz LP, Frey M, Jeschke MG. Pathophysiology of burnsDas Verbrennungstrauma: Die Pathophysiologie. Wiener Medizinische Wochenschrift 2009; 159:327–336.

  6. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hy-potension before initiation of effective antimi-crobial therapy is the critical determinant of survival in human septic shock*. Critical Care Medicine 2006; 34:1589–1596.

  7. Sen S, Greenhalgh D, Palmieri T. Review of burn research for the year 2011. Journal of Burn Care and Research 2013; 33:577–586.

  8. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Medicine 2003; 31:1250–1256.

  9. Dellinger P, Levy M, Rhodes A, Annane D, Gerlach H, Opal S, et al. Surviving Sepsis Campaign: International Guidelines for Man-agement of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013; 41:580–637.

  10. Wynn J, Cornell TT, Wong HR, Shanley TP, Wheeler DS. The host response to sepsis and developmental impact. Pediatrics 2010; 125:1031–1041.

  11. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. New England Jour-nal of Medicine 2003; 348:138–150.

  12. Fazal N. T Cell Suppression in Burn and Septic Injuries. In: Immunosuppression - Role in Health and Diseases. In Tech; 2012. p. 161–190

  13. Muñoz B, Suárez-Sánchez R, Hernández-Hernández O, Franco-Cendejas R, Cortés H, Magaña JJ. From traditional biochemical signals to molecular markers for detection of sepsis after burn injuries. Burns 2019; 45:16–31.

  14. Baron P, Traber LD, Traber DL, Nguyen T, Hollyoak M, Heggers JP, et al. Gut Failure and Translocation Following Burn and Sep-sis. Journal of Surgical Research 1994; 57:197–204. Published online: 1994.

  15. Baskin T, Rosenthal A, Pruitt B. Acute Bac-terial Endocarditis: A Silent Source of Sepsis in the Burn Patient. Annals of Surgery 1976; 184:618–621.

  16. Fitzwater J, Purdue GF, Hunt JL, O’keefe GE. The risk factors and time course of sep-sis and organ dysfunction after burn trauma. Journal of Trauma 2003; 52:959–966.

  17. Singh V, Devgan L, Bhat S, Milner SM. The pathogenesis of burn wound conversion. Annals of Plastic Surgery 2007; 59:109–115.

  18. Bratu LM, Rogobete AF, Sandesc D, Bedreag OH, Tanasescu S, Nitu R, et al. The Use of Redox Expression and Associat-ed Molecular Damage to Evaluate the In-flammatory Response in Critically Ill Patient with Severe Burn. Biochemical Genetics 2016; 54:753–768.

  19. Orman MA, Ierapetritou MG, Berthiaume F, Androulakis IP. The dynamics of the early in-flammatory response in double-hit burn and sepsis animal models. Cytokine 2011; 56:494–502.

  20. Williams FN, Herndon DN, Jeschke MG. The Hypermetabolic Response to Burn Injury and Interventions to Modify this Response. Clin-ics in Plastic Surgery 2009; 36:583–596.

  21. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn Wound Infections. Clinical Microbiology Reviews 2006; 19:403 LP – 434.

  22. Barber RC, Chang LYE, Arnoldo BD, Purdue GF, Hunt JL, Horton JW, et al. Innate im-munity SNPs are associated with risk for se-vere sepsis after burn injury. Clinical Medi-cine and Research 2006; 4:250–255.

  23. Kang J-W, Kim S-J, Cho H-I, Lee S-M. DAMPs activating innate immune responses in sepsis. Ageing Research Reviews 2015; 24:54–65.

  24. Schneider DF, Glenn CH, Faunce DE. Innate Lymphocyte Subsets and Their Immuno-regulatory Roles in Burn Injury and Sepsis. Journal of Burn Care & Research 2007; 28:365–379.

  25. De Pablo R, Monserrat J, Prieto A, Alvarez-Mon M. Role of Circulating Lymphocytes in Patients with Sepsis. BioMed Research In-ternational 2014; 2014.

  26. Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host innate immune re-sponses to sepsis. Virulence 2014; 5:36–44.

  27. Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sep-sis. Journal of Cellular and Molecular Medi-cine 2008; 12:2245–2254.

  28. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. Journal of Thrombosis and Haemostasis 2011; 9:182–188.

  29. Vandijck DM, Brusselaers N, Blot SI. In-flammatory markers in patients with severe burn injury: What is the best indicator of sep-sis? Burns 2007; 33:939–940.

  30. Rousseau A-F, Layios N. Serum Markers of Sepsis in Burn Patients: It Takes More to Convince! Critical Care Medicine 2015; 43.

  31. Pileri D, Accardo Palombo A, D’Amelio L, D’Arpa N, Amato G, Masellis A, et al. Con-centrations of cytokines IL-6 and IL-10 in plasma of burn patients: their relationship to sepsis and outcome. Annals of burns and fire disasters 2008; 21:182–185.

  32. Yeh FL, Lin WL, Shen HD, Fang RH. Changes in circulating levels of interleukin 6 in burned patients. Burns 1999; 25:131–136.

  33. Kraft R, Herndon DN, Finnerty CC, Cox RA, Song J, Jeschke MG. Predictive Value of IL-8 for Sepsis and Severe Infections After Burn Injury: A Clinical Study. Shock 2015; 43.

  34. Zhang B, Huang YH, Chen Y, Yang Y, Hao ZL, Xie SL. Plasma tumor necrosis factor-α, its soluble receptors and interleukin-1β lev-els in critically burned patients. Burns 1998; 24:599–603.

  35. Yeh FL, Lin WL, Shen HD, Fang RH. Changes in serum tumour necrosis factor-α in burned patients. Burns 1997; 23:6–10.

  36. Mokline A, Garsallah L, Rahmani I, Jerbi K, Oueslati H, Tlaili S, et al. Procalcitonin: a di-agnostic and prognostic biomarker of sepsis in burned patients. Annals of burns and fire disasters 2015; 28:116–120.

  37. Mann EA, Wood GL, Wade CE. Use of pro-calcitonin for the detection of sepsis in the critically ill burn patient: A systematic review of the literature. Burns 2011; 37:549–558.

  38. Neely AN, Fowler LA, Kagan RJ, Warden GD. Procalcitonin in Pediatric Burn Patients: An Early Indicator of Sepsis? Journal of Burn Care and Rehabilitation 2004; 25:76–80.

  39. Becker KL, Snider R, Nylen ES. Procalciton-in in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. British Journal of Pharmacology 2010;

  40. Faix JD. Biomarkers of sepsis. Critical Re-views in Clinical Laboratory Sciences 2013; 50:23–36.

  41. Yang Y, Xie J, Guo F, Longhini F, Gao Z, Huang Y, et al. Combination of C-reactive protein, procalcitonin and sepsis-related or-gan failure score for the diagnosis of sepsis in critical patients. Annals of Intensive Care 2016; 6:51.

  42. Madenci ÖÇ, Yakupoğlu S, Benzonana N, Yücel N, Akbaba D, Kaptanağası AO. Evalu-ation of soluble CD14 subtype (presepsin) in burn sepsis. Burns 2014; 40:664–669.

  43. Zou Q, Wen W, Zhang X-C. Presepsin as a novel sepsis biomarker. World journal of emergency medicine 2014; 5:16–19.

  44. Hildebrand F, Pape H-C, Harwood P, Müller K, Hoevel P, Pütz C, et al. Role of adhesion molecule ICAM in the pathogenesis of polymicrobial sepsis. Experimental and Toxi-cologic Pathology 2005; 56:281–290.

  45. Duan X, Berthiaume F, Yarmush D, Yar-mush ML. Proteomic analysis of altered pro-tein expression in skeletal muscle of rats in a hypermetabolic state induced by burn sep-sis. Biochemical Journal 2006; 397:149 LP – 158.

  46. Hashiguchi N, Ogura H, Tanaka H, Koh T, Nakamori Y, Noborio M, et al. Enhanced Ex-pression of Heat Shock Proteins in Activated Polymorphonuclear Leukocytes in Patients with Sepsis. Journal of Trauma and Acute Care Surgery 2001; 51.

  47. McConnell KW, Fox AC, Clark AT, Chang N-YN, Dominguez JA, Farris AB, et al. The Role of Heat Shock Protein 70 in Mediating Age-Dependent Mortality in Sepsis. The Journal of Immunology 2011; 186:3718–3725.

  48. Accardo-Palumbo A, D’Amelio L, Pileri D, D’Arpa N, Mogavero R, Amato G, et al. Re-duction of plasma granzyme A correlates with severity of sepsis in burn patients. Burns 2010; 36:811–818.

  49. Ramnath RD, Ng SW, Guglielmotti A, Bhatia M. Role of MCP-1 in endotoxemia and sep-sis. International Immunopharmacology 2008; 8:810–818.

  50. Hong T-H, Chang C-H, Ko W-J, Lin C-F, Liu H-H, Chow L-P, et al. Biomarkers of early sepsis may be correlated with outcome. Journal of Translational Medicine 2014; 12:146.




2020     |     www.medigraphic.com